Evolution Advisers
BMY icon

Evolution Advisers’s Bristol-Myers Squibb BMY Stock Holding History

Evolution Advisers’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-8
Closed – – 171
2026
Q2 		$0 Buy
+8
New +$459 ﹤0.01% 298
2023
Q4 		– Sell
-180
Closed -$10K – 215
2023
Q3 		$10K Hold
180
– – 0.01% 106
2023
Q2 		$11K Hold
180
– – 0.01% 110
2023
Q1 		$12K Hold
180
– – 0.01% 105
2022
Q4 		$12K Hold
180
– – 0.01% 114
2022
Q3 		$12K Sell
180
-220
-55% -$16K 0.01% 100
2022
Q2 		$30K Hold
400
– – 0.02% 80
2022
Q1 		$29K Buy
+400
New +$26.9K 0.02% 83

Other funds holding BMY

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Pzena Investment Management
Pzena Investment Management New York $34.1B AUM 26.62% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Amundi
Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $54.1B AUM 39.29% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $87.8B AUM 20.94% 1-Year Est. Return
Mitsubishi UFJ Asset Management
Mitsubishi UFJ Asset Management Tokyo, Japan $194B AUM 32.2% 1-Year Est. Return

Evolution Advisers's BMY Position: Q3 2026 in Review

Evolution Advisers sold out of Bristol-Myers Squibb (BMY) in Q3 2026, closing a stake of 8 shares.

Evolution Advisers first reported a position in BMY in Q1 2022 and held it in 8 quarters. The position peaked at $30K in Q2 2022. 1,520 funds tracked by Wall St. Rank hold BMY as of Q3 2026.

  • Evolution Advisers reported no remaining Bristol-Myers Squibb position as of Q3 2026 after selling out during the quarter.
  • Evolution Advisers sold 8 Bristol-Myers Squibb shares in Q3 2026.
  • Evolution Advisers first reported a position in Bristol-Myers Squibb in Q1 2022 and held it in 8 quarters.
  • Evolution Advisers's Bristol-Myers Squibb position peaked at $30K in Q2 2022.
  • 1,520 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2026.

Based on Evolution Advisers's 13F filing for Q3 2026, filed 6 Nov 2026.